Akari Therapeutics shares surge 52.05% after-hours on progress in nomacopan trials for rare diseases and orphan drug designation potential.

Akari Therapeutics Plc surged 52.05% in after-hours trading following the announcement of significant progress in clinical trials for its lead product, nomacopan, a therapy targeting rare complement-mediated immunological disorders. The company highlighted nomacopan’s potential to reduce inflammation and tissue damage, with plans to pursue orphan drug designation to accelerate development and commercialization. This advancement, coupled with the product’s alignment with unmet medical needs in rare diseases, likely drove the sharp after-hours increase, reflecting investor optimism about the therapy’s regulatory and market potential.